Slide 1: Moderna ESG Day
Moderna ESG Day November 10th, 2022 © 2022 M oderna, Inc. All rights reserved.
Slide 2: Forward-looking statements and disclaimer
Forward-looking statements and disclaimer This presentation contains forw ard-looking statements w ithin the meaning of the Priv ate Securities Litigation Reform Act of 1995, as amended, including statements regarding: the impact of a fall COVI D-19 booster campaign on liv es and dollars sav ed; the
Slide 3: Moderna's mission and five focus areas of our corporate responsibility framework
Moderna’s mission and five focus areas of our corporate responsibility framework To deliver on the promise of mRNA science to create a new generation of transformative medicines for patients. 3 © 2022 M oderna, Inc. All rights reserved. https://assets.modernatx.com/m/ccaae809ca9152c/original/Moderna
Slide 4: Today is Moderna's first ESG Day
Today is Moderna’s first ESG Day Launched corporate social responsibility framework in 2018 Released first Environmental, Social and Governance (ESG) report in June 2022 Today’s goal is to engage stakeholders, highlight progress and be transparent on our ESG journey https://assets.modernatx.com/m/cc
Slide 5: Medicines for patients
Medicines for patients MEDICINES FOR PATIENTS 5 © 2022 M oderna, Inc. All rights reserved.
Slide 6: Diverse portfolio of vaccine and therapeutic programs
Moderna has a diverse portfolio of vaccine and therapeutic programs in preclinical and clinical development Preclinical Phase 1 Phase 2 Phase 3 Licensed mRNA-1273 SARS-CoV-2 mRNA-1345 RSV (older adults) mRNA-1010 Seasonal Flu (HA) mRNA-1283 SARS-CoV-2 mRNA-1073 COVID + Flu Respiratory Infectious mRN
Slide 7: mRNA technology enabled rapid development of infectious disease vaccines portfolio
Moderna’s mRNA technology has enabled the rapid development of our infectious disease vaccines portfolio Preclinical Phase 1 Phase 2 Phase 3 Licensed mRNA-1273 SARS-CoV-2 mRNA-1345 RSV (older adults) mRNA-1010 Seasonal Flu (HA) mRNA-1283 SARS-CoV-2 mRNA-1073 COVID + Flu Respiratory Infectious mRNA-1
Slide 8: Impact of safe and effective vaccines on global health
The impact of safe and effective vaccines on global health, economies and social welfare is undeniable We have had the privilege of protecting hundreds of millions of people in 2021 & 2022 with our COVID vaccines Resulting in an estimated 1.7 million deaths averted in 2021 because of Moderna’s vacci
Slide 9: 26 in the clinic, 4 in Phase 3, 3 approved products
We hope to have a large impact on human health with many more of our vaccines Moderna’s mRNA platform enables us to rapidly develop many vaccines, potentially allowing us to address significant unmet medical needs In our prophylactic vaccine modality, Our m RNA vaccine technology advantages we have:
Slide 10: Climate change is aggravating human pathogenic diseases
Climate change is aggravating human pathogenic diseases A pathogen and a person coming into contact is the most important factor for the emergence of a human pathogenic disease Climate change is leading to a shift in the geographical Subset of diseases aggravated by climatic hazards range of species
Slide 11: Utilizing mRNA technology to accelerate pandemic preparedness globally
Utilizing our mRNA vaccine technology to accelerate pandemic preparedness globally Priority mRNA Regional Pathogens Access™ Manufacturing New collaborative access Commitment to Operate mRNA manufacturing enabling researchers around advance vaccines facilities around the world the world to utilize Mo
Slide 12: Our mRNA therapeutics pipeline addresses unmet medical needs
Our mRNA therapeutics pipeline addresses unmet medical needs and has the potential to transform the lives of many patients Preclinical Phase 1 Phase 2 Phase 3 Licensed mRNA-1273 SARS-CoV-2 mRNA-1345 RSV (older adults) mRNA-1010 Seasonal Flu (HA) mRNA-1283 SARS-CoV-2 mRNA-1073 COVID + Flu Respiratory
Slide 13: Moderna-Institute For Life Changing Medicines (ILCM) collaboration
Moderna-Institute For Life Changing Medicines (ILCM) collaboration • Crigler-Najjar syndrome is a severe condition that can lead to jaundice and damage to the brain, muscles and nerves. The symptoms become apparent shortly after birth and can be life-threatening – It is estimated that there are only
Slide 14: We are committed to reach as many people as possible
We are committed to reach as many people as possible Moderna’s Commitment to Vaccines and Therapeutics Access December 23, 2020 Moderna is committed to developing a broad portfolio of vaccines and therapeutic solutions to address 1 epidemiological challenges worldwide 2 Moderna will invest in R&D in
Slide 15: Employees
Employees EMPLOYEES 15 © 2022 M oderna, Inc. All rights reserved.
Slide 16: Moderna seeks to attract and retain the best talent
Moderna seeks to attract and retain the best talent • Patients/people and the impact first • Diversity & inclusion efforts • Employee resource groups • Ensuring employees have financial and mental well-being 16 © 2022 M oderna, Inc. All rights reserved.
Slide 17: Environment
Environment ENVIRONMENT 17 © 2022 M oderna, Inc. All rights reserved.
Slide 18: Climate change is increasingly affecting the foundations of human health
Climate change is increasingly affecting the foundations of human health Moderna is committed to achieve net-zero carbon emissions in our global operations (Scopes 1 & 2) by 2030 For Scope 3, Moderna is committed to defining a near-term science-based target and evaluating a long-term target 18 © 202
Slide 19: Community
Community COMMUNITY 19 © 2022 M oderna, Inc. All rights reserved.
Slide 20: Committed to having a positive impact on communities
Committed to having a positive impact on communities around the world Corporate Employee Philanthropic Humanitarian Volunteering Gift Matching Giving Relief 20 © 2022 M oderna, Inc. All rights reserved.
Slide 21: Governance & Ethics
Governance & Ethics GOVERNANCE & ETHICS 21 © 2022 M oderna, Inc. All rights reserved.
Slide 22: Building Moderna in the right way
Building Moderna in the right way ESG accountability at Board and Executive Committee level Starting our journey by increasing transparency across our supply chain Increased disclosure of ESG data and our progress 22 © 2022 M oderna, Inc. All rights reserved.
Slide 23: Today's agenda
Today’s agenda Moderna's Mission and Culture to Drive Impact Stéphane Bancel, Chief Executive Officer Medicines for Patients Overview of mRNA Vaccines and Therapeutics Stephen Hoge, President Inclusive Research at Moderna Jameka Hill, Director, Patient Engagement and Trial Diversity Global Health St
Slide 24: Overview of mRNA Vaccines and Therapeutics
Overview of mRNA Vaccines and Therapeutics Stephen Hoge, M.D. President © 2022 M oderna, Inc. All rights reserved.
Slide 25: mRNA is a new class of medicine
mRNA is a new class of medicine 25 © 2022 M oderna, Inc. All rights reserved.
Slide 26: How we accelerate our development pipeline
How we accelerate our development pipeline EXPLORATORY EMERGING ESTABLISHED Inhaled Localized Intratumoral Cancer Systemic secreted Systemic Prophylactic Modalities pulmonary regenerative immuno- vaccines & cell surface intracellular vaccines therapeutics therapeutics oncology therapeutics therapeut
Slide 27: Late stage pipeline potential impact across several therapeutic areas
Moderna’s late stage pipeline has the potential to have meaningful impact across several therapeutic areas Respiratory infections are a Approximately 4% of the Cancer impacts large top cause of death globally total world population is portions of the population (3 million deaths) affected by a rare
Slide 28: Two key aspects of our R&D organization
Today you will hear about two key aspects of our R&D organization Diversity and inclusion in Global health strategy clinical trials • Investing to be the leader in • Aiming to enhance capabilities diversity & inclusion in clinical and infrastructure to improve trials global health outcomes, includin
Slide 29: Inclusive Research at Moderna
Inclusive Research at Moderna Jameka Hill Director, Patient Engagement and Trial Diversity © 2022 M oderna, Inc. All rights reserved.
Slide 30: Why is diversity in clinical trials so important?
Why is diversity in clinical trials so important? Drugs and vaccines are safer and more effective for everyone when clinical trials include everyone • People of different ages, sexes, races, and ethnicities may react differently to certain medicines and vaccines • When a clinical trial population is
Slide 31: How does Moderna define diversity in clinical research?
How does Moderna define diversity in clinical research? • Diversity exists across many dimensions • Diversity is context-specific • The importance of each factor may vary depending upon the disease/condition and the population at risk 31 © 2022 M oderna, Inc. All rights reserved.
Slide 32: Women and minorities historically underrepresented in clinical trials
Women and minorities have historically been underrepresented in clinical trials Year Regulatory Efforts to Address Underrepresentation The National Institutes of Health (NIH) adopted a policy in 1993 1993 mandating all federal grants for clinical research include women and minorities. The FDA launch
Slide 33: Reluctance to participate in clinical trials
Reluctance to participate in clinical trials Mistrust Limited Awareness of Trials Lack of Invitation to Participate Lack of Information Logistical Obstacles – Time & Resource Constraints Complexity of Protocol – Study Burden Ethnic & Cultural Beliefs Language/Literacy Eligibility Criteria/Comorbid C
Slide 34: What constitutes diversity in Moderna clinical trials
What constitutes diversity in Moderna clinical trials Race, ethnicity, age, and sex can all impact how different people respond to the same medicine or vaccine At Moderna, a clinical trial can be qualified as “diverse” in healthy volunteer trials when: 49.6% • 37% of the sample population within the
Slide 35: Diversity in clinical trials: where we were in 2020
Diversity in clinical trials: where we were in 2020 60% 75% White Hispanic/Latinx Black/African American Asian All others 18% 11% 13% 8% 6% 6% 3% U.S. Population (2020) Percent Participation in Clinical Trials by Subpopulation for New Molecular Entities and Therapeutic Biologics Approved (2020) Sour
Slide 36: Moderna's approach to reach underrepresented groups
Moderna’s approach to reach underrepresented groups Drive strategy and manage initiatives to build trust and ensure medically underrepresented groups can be better engaged in our clinical trials • Embed the importance of diversity in clinical trials into our company’s culture • Establish demographic
Slide 37: Enrolled diverse and at-risk populations for Phase 3 COVE study
Ensured that we enrolled diverse and at-risk populations for our Phase 3 COVID-19 vaccine trial (COVE Study) Announced a slowing of Pivotal Enrollment enrollment to ensure the Slowed enrollment in the Phase 3 COVE completed of representation of study begins Phase 3 study COVE study to ensure communi
Slide 38: COVE study: Racial ethnic demographics
COVE study: Racial ethnic demographics White Hispanic/Latinx Black/AA COVE Study Participants Count Asian All others W hite, non-Hispanic 19,060 63% 60% Hispanic or Latinx 6,247 Black or African American 3,114* Asian 1,365 Others 871^ 18% Total 30,406+ 20% * Includes 251 participants who identify as
Slide 39: Leveraging digital infrastructure to support trial diversity
Leveraging our digital infrastructure to support trial diversity Real-time D&I comparison to census • Empowered COVE clinical team decision making and made an impact for populations most at risk Shared insights across multiple teams • Shared insights from central location with Moderna teams, clinica
Slide 40: Phase 3 RSV and CMV trials on track to meet demographic objectives
Our pivotal Phase 3 trials in RSV and CMV are both on track to meet demographic objectives US Enrollment Targets Based on US Enrollment Targets Based on Demographic Composition Demographic Composition Objective Current % Objective Current % White 69% 65% White 58% 52% Persons of color 31% 35% Person
Slide 41: Striving to be a leader in the industry
Striving to be a leader in the industry Moderna continues to lead the industry, proving that concerted efforts to provide equitable healthcare access to all populations are both possible and essential. U.S. Participants of Color Across 13 Vaccine Trials (Phase 1-3) 56% 56% % (n) (19,841) (1,872) 53%
Slide 42: Summary
Summary Clinical trial diversity is not solely our ethical responsibility – it is also a scientific imperative Moderna leverages our digital infrastructure to enable meaningful action through real time data transparency Improving trial diversity is a vital step towards achieving health equity and he
Slide 43: Moderna's Global Health Strategy
Moderna’s Global Health Strategy Hamilton Bennett Senior Director, Vaccine Access & Partnerships © 2022 M oderna, Inc. All rights reserved.
Slide 44: Committed to using our mRNA platform for global health since founding
We have been committed to using our mRNA platform for global health since our founding 2022 Leading funding & Commitment to development 2020/2021 advance vaccines partners for vaccines Development & targeting at least 15 2019 authorization of pathogens identified as Publication of mRNA-1273 biggest
Slide 45: Key pillars of our global health strategy
Key pillars of our global health strategy Priority mRNA Regional Pathogens Access™ Manufacturing New collaborative program Commitment to Operate mRNA manufacturing enabling researchers around advance vaccines facilities around the world the world to utilize Moderna’s targeting at least 15 to be read
Slide 46: Priority pathogens
Priority pathogens Priority mRNA Regional Pathogens Access™ Manufacturing New collaborative access Commitment to Operate mRNA manufacturing enabling researchers around advance vaccines facilities around the world the world to utilize Moderna’s targeting at least 15 to be ready to respond to mRNA tec
Slide 47: Pandemic and epidemic threats will continue to arise
Pandemic and epidemic threats will continue to arise “Using recent estimates of the rate of increase in disease emergence from zoonotic reservoirs associated with environmental change, we estimate that the yearly probability of occurrence of extreme epidemics can increase up to threefold in the comi
Slide 48: Our platform is uniquely suited to address persistent and emerging threats
Our platform is uniquely suited to address persistent and emerging threats Persistent Global Health Threats Prototype Viral Family (WHO, CEPI and others) Chikungunya v irus Togav iridae COVI D-19 Coronav iridae Crimean-Congo haemorrhagic fev er Nairov iridae Dengue Flav iv iridae Committed to advanc
Slide 49: Meaningful progress against prioritized global health programs
Meaningful progress has been made against prioritized global health programs Priority Pathogen ID # Preclinical Dev Phase 1 Phase 2 Phase 3 Commercial Collaborators COVID-19 mRNA-1273 BARDA/NIAID Zika mRNA-1893 BARDA Chikungunya mRNA-1388 -- HIV mRNA-1644 IAVI / Others HIV mRNA-1574 IAVI/BMGF/NIAID
Slide 50: HIV: leveraging collaborations to advance programs against unmet need
HIV is an example of leveraging collaborations to advance programs against an unmet need • Belongs to a class of viruses known as retroviruses Human • Primary routes of transmission are sexual intercourse immunodeficiency and IV drug use, putting young adults at highest risk virus (HIV) of infection
Slide 51: mRNA Access
mRNA Access Priority mRNA Regional Pathogens Access™ Manufacturing New collaborative access Commitment to Operate mRNA manufacturing enabling researchers around advance vaccines facilities around the world the world to utilize Moderna’s targeting at least 15 to be ready to respond to mRNA technology
Slide 52: Mission of mRNA Access
Mission of mRNA Access Create life saving medicines: To accelerate innovation and Primary enable new medicines for emerging and neglected mission infectious disease through decentralized research and development (R&D) Additional benefits Engage Disease-Area Experts: To Inspire Future Scientists: To
Slide 53: mRNA Access Powered by Moderna
mRNA Access Powered by Moderna mRNA Design Studio High-Throughput Production Iterative Research Our custom mRNA is codon Optimized mRNA is manufactured The speed and flexibility of our optimized for optimal expression using our prophylactic vaccine platform allows for rapid design- and manufacturabi
Slide 54: mRNA Access is targeting emerging and neglected infectious diseases
mRNA Access is targeting emerging and neglected infectious diseases Existing & Planned Programs Potential Future Programs • Alkhurma virus • Dengue (flaviviridae proto) • Kyasanur Forest virus • Rickettsia (spotted fevers) • Andes virus • Eastern equine encephalitis (EEE) • Kumasi virus • Rift Valle
Slide 55: mRNA Access Collaborators
mRNA Access Collaborators 55 © 2022 M oderna, Inc. All rights reserved.
Slide 56: Regional manufacturing
Regional manufacturing Priority mRNA Regional Pathogens Access™ Manufacturing New collaborative access Commitment to Operate mRNA manufacturing enabling researchers around advance vaccines facilities around the world the world to utilize Moderna’s targeting at least 15 to be ready to respond to mRNA
Slide 57: Building regional manufacturing capability to prepare for the future
We are building regional manufacturing capability to prepare for the future Facilities around the world can be important pillars of response to any pandemic outbreak Canada UK* MA, USA Kenya Australia 57 © 2022 M oderna, Inc. All rights reserved. *agreement in principle, pending signing definitive a
Slide 58: Making progress in building infrastructure in Africa
Making progress in building infrastructure in Africa Update on Kenya manufacturing facility • Moderna announced in March 2022 that it had selected Kenya for its first manufacturing site in Africa • Site selection close to being finalized, subject to reaching an agreement with the government of Kenya
Slide 59: Summary
Summary Moderna has been committed to global health since its founding in 2010, leveraging the power of mRNA Committed to bringing forward at least 15 pathogens into the clinic in order to help prepare for any future pandemics Sharing our mRNA platform with collaborators worldwide through mRNA Acces
Slide 60: Moderna Culture & Employees
Moderna Culture & Employees Tracey Franklin Chief Human Resources Officer © 2022 M oderna, Inc. All rights reserved.
Slide 61: Moderna has expanded rapidly in the last few years
Moderna has expanded rapidly in the last few years Full Time Employees as of Dec 31 3,800 +500% 2,750 Headcount expansion: Since our IPO in 2018, we have increased our employee headcount ~5X 1,300 760 830 2018 2019 2020 2021 2022* * headcount as of October 2022 Geographic expansion: We now have empl
Slide 62: We have made progress in representation
We have made progress in representation Gender1 Race & Ethnicity2 Pay Equity3 January 2020 September 2022 Z ero All Employees 27.1% 21.2% 45.6% 50.0% Female Statistically significant 7.7% differences in pay 5.1% 6.0% 3.5% = Executives4 Jan-20 Oct-22 Jan-20 Oct-22 Jan-20 Oct-22 30.2% 41.1% Asian Hisp
Slide 63: Recruiting the best talent from around the world
Ever since Moderna was founded, we have consistently strived to recruit the best talent from around the world ~185 34 >90% >300 Employees with a Nationalities currently of our Executive Employees working Green Card represented Committee have with active visa status sponsored by lived and/or Moderna
Slide 64: Elements of our culture support rapid growth
The elements of our culture support rapid growth and drive an environment where everyone can have an impact OUR MISSION OUR VALUES OUR MINDSETS We act with We pursue options We obsess o We accept risk urgency in parallel learning To deliver on the promise of mRNA science to create a new generation o
Slide 65: Diversity and inclusion starts with belonging
Our philosophy toward diversity and inclusion starts with belonging, the most challenging but essential focus area Lead with Drive a Culture Grow Belonging of Inclusion Diversity 65 © 2022 M oderna, Inc. All rights reserved.
Slide 66: Video: Moderna employees
Video: Moderna employees https://www.modernatx.com/careers/people-behind-the-science 66 © 2022 M oderna, Inc. All rights reserved.
Slide 67: Concrete strategy to advance Belonging, Inclusion, and Diversity
We have a concrete strategy to continue to advance our Belonging, Inclusion, and Diversity efforts Roadmap We have developed a holistic five-year Belonging, Inclusion & Diversity roadmap Internal Moderna’s nine employee resource groups are focused both on affinity and enhancing enhancing the company
Slide 68: Advanced listening tools to identify areas of focus
We adopt advanced listening tools to identify areas of focus to create an environment where our unique workforce can have the most impact Learning Well-being 68 © 2022 M oderna, Inc. All rights reserved.
Slide 69: Elevating learning at Moderna will help write our next chapter
Elevating learning at Moderna will help us write our next chapter Our vision for learning at Moderna Moderna becomes a 'beacon of education' and recognized globally as the pre-eminent talent development destination in biopharma and beyond. We achieve this by providing innovative and transformational
Slide 70: Investing in learning enables us to give back
Investing in learning enables us to give back internally and externally AI Academy • Experiential learning and dev elopment of use cases Transforming the industry through • As of Nov ember 2022, more than 400 education about the pow er of AI to employees hav e gone through the 3-day accelerate outco
Slide 71: Customized total rewards to support employee well-being
We’ve developed a customized set of total rewards to support the well-being of our employees Primary domains of employee health and well-being at Moderna Physical Mental Occupational Financial Social 71 © 2022 M oderna, Inc. All rights reserved.
Slide 72: Holding ourselves accountable to key employee metrics
We measure and hold ourselves accountable to how we’re performing against key employee metrics We consistently achieve above benchmark scores on engagement, culture, and belonging Engagement Culture Belonging Benchmark 73 Benchmark 64 Benchmark 70 78 73 74 Since 2021 we’ve included a belonging metri
Slide 73: Communities
Communities Katherine O’Malley Executive Director, Internal Communications and Employee Engagement © 2022 M oderna, Inc. All rights reserved.
Slide 74: Vulnerable communities disproportionally impacted by COVID-19
Vulnerable communities have been disproportionally impacted by the COVID-19 pandemic Unequal negative effects on the broader social determinants of health observed in 2021 2 Access to Social affordable & inclusion & quality non- healthcare Close to 95 million Job losses affecting Housing discriminat
Slide 75: We strive to extend our positive impact on society
We strive to extend our positive impact on society Corporate Employee Philanthropic Humanitarian Volunteering Gift Matching Giving Relief Annual #VolunteerWeek $1 million donation to support New “Dollars for doers” humanitarian relief program efforts in Ukraine and Launched in 2022 Eastern Europe 75
Slide 76: Engaging with our communities is critical to deliver on mRNA promise
Engaging with our communities is critical to deliver on the promise of mRNA STEM Education Day at Fenway Park, October 2022 Engage the next generation of scientists Address health literacy gap across our communities Close the opportunity gap in underserved communities "There’s nothing more normal "V
Slide 77: Launched Moderna Charitable Foundation in 2022
Launched Moderna Charitable Foundation in 2022 The Moderna Foundation reflects our commitment to giving back to help ensure a stronger and more equitable post-pandemic world through grants, humanitarian support and a new employee matching gift program. Philanthropic giving Initial grant partners: Wi
Slide 78: Promoting public health and access to quality healthcare
Promoting public health and access to quality healthcare Focused on improving health systems and healthcare in sub-Saharan Africa • Moderna Foundation awarded a total of $4 million to three organizations focused on improving health systems and healthcare in sub-Saharan Africa Link to more detail 78
Slide 79: Case study: Moderna Foundation partnering with Seed Global Health
Case study: Moderna Foundation is partnering with Seed Global Health for long-lasting impact and change at system level https://www.youtube.com/ watch?v=ZPCr-hGkLLw 79 © 2022 M oderna, Inc. All rights reserved.
Slide 80: Case study: Moderna Foundation partnering with Seed Global Health
Case study: Moderna Foundation is partnering with Seed Global Health for long-lasting impact and change at system level Dedicated to support our partners in sub-Saharan Africa to create lasting change in the health system. Current partner countries include: Malawi, Sierra Leone, Uganda, and Zambia.
Slide 81: Coffee break: To resume in 5 minutes
Coffee break: To resume in 5 minutes Moderna's Mission and Culture to Drive Impact Stéphane Bancel, Chief Executive Officer Medicines for patients Overview of mRNA vaccines and therapeutics Stephen Hoge, President Inclusive research at Moderna Jameka Hill, Director, Patient Engagement and Trial Dive
Slide 82: Environment
Environment Deborah Donovan Senior Vice President, Environmental, Health & Safety, Technical Development & Manufacturing © 2022 M oderna, Inc. All rights reserved.
Slide 83: Human activity has a clear impact on atmospheric conditions
Human activity has a clear and visible impact on atmospheric conditions 83 © 2022 M oderna, Inc. All rights reserved.
Slide 84: Climate change is increasingly affecting the foundations of human health
Climate change is increasingly affecting the foundations of human health The 2022 report of the Lancet Countdown on health and climate change: health at the mercy of fossil fuels 68% heat-related deaths increase between 2000–04 and 2017–21 253b $ damage worth in 2021 caused by extreme weather events
Slide 85: Climate policy developments over time
Climate policy developments over time 1992 2015 Science Based Targets initiative (SBTi) and UN Framework Task force on Climate Related Financial Convention on Climate Disclosures (TCFD) are established Change is established 1972 1995 1997 2015 2022 UN Environment First Conference of Kyoto Protocol P
Slide 86: Greenhouse Gas Protocol Standards for emissions inventory
We follow the Greenhouse Gas Protocol Standards for development of our emissions inventory GHG from human activities (e.g., CO2, CH4, N20, HCFs, etc.) are accounted for in three “scopes” Scope 1 Direct emissions from owned or controlled sources (e.g., fossil fuels usage) Scope 2 Indirect emissions f
Slide 87: Urgency to limit global warming to 1.5°C
We understand the urgency to limit global warming to 1.5°C Moderna is committed to achieve net-zero carbon emissions in our global operations (Scopes 1 & 2) by 2030 For Scope 3, Moderna is committed to defining a near-term science-based target and evaluating a long-term target 87 © 2022 M oderna, In
Slide 88: Joining companies taking action to halve carbon emissions
We are joining companies taking action to halve carbon emissions The Science Based Targets initiative (SBTi) drives ambitious climate action in the private sector by enabling organizations to set science-based emissions reduction targets. In partnership with: How it works: Moderna has Moderna is pre
Slide 89: Committed to protecting the planet
As we scale our company, we are committed to protecting the planet Environmental Sustainability Strategy Sustainability by Natural Resource Decarbonize Design Conservation Value Chain Current focus areas: LEED design in new Net-zero carbon Partner with suppliers sites and buildings emissions in glob
Slide 90: Building a new low-carbon HQ and R&D building in Cambridge
Building a new HQ and R&D operations low-carbon building in Cambridge RENEWABLE ELECTRICITY LEED Platinum Solar Array Core & Shell and LEED Zero Energy GEOTHERMAL SYSTEM Fossil Fuel Reduction for Heating/Cooling 92% reduction in fossil fuel use CLIMATE RESILIENCE 100% of building energy Stormwater C
Slide 91: Taking first steps in our journey
Taking first steps in our journey Established 2021 base year emissions for Scopes 1 & 2 (3rd party data assurance pending) 2021 CO2e Emissions (metric tons) Natural Resource 9,600 Conservation 7,200 LBE LBE: location-based emissions 50 MBE MBE: market-based emissions Scope 1 Scope 2 Covered 100% of
Slide 92: Scope 3 accounts for more than 90% of carbon emissions
Similar to peers in pharma and biotech, Scope 3 accounts for more than 90% of our carbon emissions Moderna Moderna Scope 1 & 2 Scope 3 Tier 1 Suppliers Tier 1 Suppliers Scope 3 Scope 1 & 2 Tier 2 Suppliers Tier 2 Suppliers Scope 3 Scope 1 & 2 Tier n Suppliers Tier n Suppliers Scope 3 Scope 1 & 2 Whe
Slide 93: Understanding the carbon footprint of our value chain
Already taking steps to understand the carbon footprint of our value chain Established 2021 GHG Scope 3 Baseline, pending third party verification Committed to define near-term science-based target and evaluate long-term Scope 3 target Decarbonize Value Chain 100% subsidized green transportation acr
Slide 94: Seeking solutions to decarbonize value chain
Already seeking solutions to decarbonize value chain HVO Pilot with Kuehne+Nagel 3,700 KM (2,300 mi) round trip One fuel-up with HVO Mission to reduce CO2 by 90% What is Hydrotreated Vegetable Oil (HVO) fuel? High quality diesel fuel made from renewable, sustainable raw materials, e.g., food waste.
Slide 95: Continuing our journey and focus on key milestones
We will continue our journey and focus on key milestones Complete climate risk scenario analysis Submit science-based targets for official validation by SBTi Intention to report to CDP and align with TCFD recommendations 95 © 2022 M oderna, Inc. All rights reserved.
Slide 96: Governance & Ethics
Governance & Ethics Shannon Thyme Klinger Chief Legal Officer & Corporate Secretary © 2022 M oderna, Inc. All rights reserved.
Slide 97: Board of Directors – Current Composition
Board of Directors – Current Composition Noubar Afeyan, PhD Sandra Horning, MD Elizabeth (Betsy) Nabel, M.D. Co-founder and Chairman, Co-Founder and Advisor, EQRx; Executive Vice President for Strategy Moderna; CEO, Flagship Former Chief Medical Officer of at ModeX Therapeutics; former Pioneering Ge
Slide 98: 2022 Board Highlights
2022 Board Highlights From 2021 Proxy Statement 98 © 2022 M oderna, Inc. All rights reserved.
Slide 99: ESG oversight starts with the Board and Committees
ESG oversight starts with the Board and Committees Board Committees ESG oversight: Compensation and Talent Nominating and Corporate Product Development Audit Committee Committee Governance Committee Committee • Risk Assessment & • Human Capital • ESG strategy and metrics • Clinical trial design, inc
Slide 100: Embedding accountability for ESG throughout the organization
Moderna continues to embed accountability for ESG throughout the organization ESG accountability at Executive Committee level: Overseeing additional elements of ESG initiatives • Shannon Klinger, Chief Legal Officer leads Moderna’s ESG strategy • Juan Andres / Jerh Collins, Chief Technical Operation
Slide 101: Evolving our Compliance policies, aligned with our values
Evolving our Compliance policies, aligned with our values Moderna’s Code of Ethics & Business Conduct is our guide for ethical decision making – doing the right thing, the right way, every day! Effective January 1, 2023, Moderna’s reimagined, principles-based Code of Ethics & Business Conduct: #Livi
Slide 102: Building a supply chain that reflects our values
Building a supply chain that reflects our values Starting our journey by increasing transparency across our supply chain • Implemented Third Party Code of Business Conduct* outlining our expectations of suppliers 2022-2023 • Launching Sustainable & Responsible Procurement program & assessment of key
Slide 103: Commitment to transparency since the beginning of our journey
Committment to transparency since the beginning of our journey Key highlights 2021 / 2022 Published first 2021 ESG Report Increased disclosure of ESG data and journey 2021 U.S. EEO-1 report Published GHG 2021 Scopes 1 & (U.S. workforce diversity) 2 data (verification pending) Trade association discl
Slide 104: Concluding Remarks
Concluding Remarks Stéphane Bancel Chief Executive Officer © 2022 M oderna, Inc. All rights reserved.
Slide 105: Our ESG journey will help Moderna become one of the most impactful companies
We believe our ESG journey will help Moderna become one of the most impactful companies With the potential of our science comes a responsibility to the multitude of patients our technology could help We have a responsibility to our employees to provide fulfilling, purposeful careers, and that our em
Slide 106: Thank you
Collaborators, investigators, Thank you patients and their families, employees and investors…! © 2022 M oderna, Inc. All rights reserved.